Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $6.63 Consensus Price Target from Analysts

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) has been given a consensus rating of “Buy” by the eight brokerages that are currently covering the company, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $6.63.

TSHA has been the subject of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research report on Monday, April 28th. Chardan Capital reiterated a “buy” rating and set a $7.00 price objective on shares of Taysha Gene Therapies in a research note on Wednesday, February 26th. Needham & Company LLC restated a “buy” rating and issued a $6.00 price target on shares of Taysha Gene Therapies in a research note on Thursday, April 10th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $5.00 price objective on shares of Taysha Gene Therapies in a report on Monday, April 28th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TSHA. Octagon Capital Advisors LP grew its position in Taysha Gene Therapies by 128.6% during the fourth quarter. Octagon Capital Advisors LP now owns 10,450,000 shares of the company’s stock worth $18,078,000 after buying an additional 5,877,778 shares in the last quarter. Adage Capital Partners GP L.L.C. bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth $8,650,000. Bank of America Corp DE raised its stake in Taysha Gene Therapies by 1,178.9% in the fourth quarter. Bank of America Corp DE now owns 1,710,303 shares of the company’s stock valued at $2,959,000 after purchasing an additional 1,576,568 shares in the last quarter. Norges Bank acquired a new position in Taysha Gene Therapies in the fourth quarter valued at about $2,528,000. Finally, Avoro Capital Advisors LLC lifted its holdings in shares of Taysha Gene Therapies by 7.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 19,999,999 shares of the company’s stock worth $34,600,000 after acquiring an additional 1,349,999 shares during the period. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Stock Performance

Shares of Taysha Gene Therapies stock opened at $2.58 on Wednesday. The company has a market capitalization of $529.04 million, a PE ratio of 4.10 and a beta of 0.96. The company has a current ratio of 5.51, a quick ratio of 5.51 and a debt-to-equity ratio of 0.48. The stock’s fifty day simple moving average is $1.59 and its 200 day simple moving average is $1.80. Taysha Gene Therapies has a 12 month low of $1.05 and a 12 month high of $4.32.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.01. Taysha Gene Therapies had a negative net margin of 229.67% and a negative return on equity of 106.36%. The firm had revenue of $2.02 million for the quarter, compared to analyst estimates of $2.05 million. On average, research analysts predict that Taysha Gene Therapies will post -0.35 EPS for the current year.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.